(Q34481466)

2 August 2017

1 reference

title

Liposomal cancer chemotherapy: current clinical applications and future prospects (English)

1 reference

2 August 2017

1 reference

Harrington KJ

1

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

Expert Opinion on Investigational Drugs

2 August 2017

published in

1 reference

2 August 2017

volume

10

1 reference

2 August 2017

issue

6

1 reference

2 August 2017

page(s)

1045-1061

1 reference

The carrier potential of liposomes in biology and medicine (second of two parts)

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Preliminary report: imaging of Kaposi sarcoma and lymphoma in AIDS with indium-111-labelled liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Liposomal doxorubicin for treatment of AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Phase II study of liposomal doxorubicin in advanced gynecologic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Administration of a modified chemotherapeutic regimen containing vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma patients: preliminary data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Single-fraction irradiation has no effect on uptake of radiolabeled pegylated liposomes in a tumor xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Immunoliposomes for the targeted delivery of antitumor drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferring receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Uptake and processing of immunoglobulin-coated liposomes by subpopulations of rat liver macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Development of anti-p185HER2 immunoliposomes for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Genetics of multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

P-glycoprotein, multidrug resistance and tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

MDR1 gene expression in solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

mdr1 mRNA expression by RT-PCR in patients with primary breast cancer submitted to neoadjuvant therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

MDR1 gene expression and prognostic factors in primary breast carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

MDR1 gene expression and its clinical relevance in primary gastric carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Effect of liposomes on P-glycoprotein function in multidrug resistant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Liposome-encapsulated daunorubicin for PGP-related multidrug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1045

10.1517/13543784.10.6.1045

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference